Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)

Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)

US Patent 11701418 · Granted Jul 18, 2023

Estimated economic value: $753,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus gl2025
Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus gl2025
Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus gl2025
Compositions and methods for generating an immune response to treat or prevent m2025
Vaccinia viral vectors encoding chimeric virus like particles2025
Vaccinia viral vectors encoding chimeric virus like particles2025
Vaccinia viral vectors encoding chimeric virus like particles2025
Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus gl2024
Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus gl2024
Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus gl2024
Multivalent HIV vaccine boost compositions and methods of use2024
Compositions and methods for generating an immune response to treat or prevent m2024